Co-Organised Event - Toronto 14-17 June, 2018

Global Hepatitis Summit 2018


The Global Hepatitis Summit in Toronto, Ontario, Canada, June 14 - 17, 2018,  will bring together leaders from around the world to discuss outstanding basic and clinical science while addressing public health issues around viral hepatitis and other liver diseases. With a new focus on Public/Global Health and the addition of a Global Village, this promises to be a recharged ISVHLD meeting not to be missed.

AASLD, EASL and ISVHLD will host an HCC symposium on Friday 15 June 2018 during the 16th International Symposium on Viral Hepatitis and Liver Disease and invite you to attend. The HCC Symposium will bring together leading experts on to discuss the state of the art in epidemiology, surveillance, research and clinical management of HCC.

When: Friday June 15, 2018

Time: 10.30-18.00

Where: Metro Toronto Convention Centre, Toronto, Canada

The HCC Symposium is taking place as part of the Global Hepatitis Summit in Toronto, Canada from June 14th - 17th, 2018. The HCC Symposium is included in the full GHS 2018 Summit registration pass.

Hepatocellular carcinoma is an increasing threat in most countries in the world. Although there are programs that allow early detection and curative treatment most cancers are still only diagnosed late. At this late stage treatment of the cancer is complicated by the presence of liver disease, which may be advanced, and which may alter the pharmacokinetics of any drug used to treat the cancer.

Thus there are many gaps in our approach to managing this disease. We need to better understand the epidemiology, in particular why so few patients are diagnosed early. Although our knowledge of the biology of this cancer has improved by leaps and bounds in the recent past we still do not understand the pathogenesis fully, and we are unable to target metabolic pathways that might effectively treat the cancer. There has been progress in chemotherapy of advanced disease, but we are still a long way from the possibility of cure of intermediate or late stage disease.

This series of presentations at the Global Hepatitis Summit will bring together experts in several different areas of research on hepatocellular carcinoma to discuss the state of the art in their areas to highlight where we are and where we need to go in future.

Session 1 - General Session

·    Brian McMahon: Global epidemiology of HCC in the 21st Century: Changing etiology of liver disease

·    Thomas Baumert: Pathogenesis of HCC: Genetic and epigenetic factors

·    Morris Sherman: HCC surveillance: How, When and What to do with a positive result

·    David Kaplan: Strategies to improve Healthcare delivery for HCC: A Multidisciplinary approach


Session 2 - Hepatitis B and HCC

·    Massimo Levrero: Oncogenesis of HBV-related HCC – virus vs. inflammation

·    Lewis Roberts: Epidemiology of HBV-related HCC – continental perspectives

·    George Papatheordorides: Assessing HCC risk in Hepatitis B: How to use different scoring systems

·    Ray Kim: Development of HCC in patients with suppressed viral replication: Changes in risk over time


Session 2 - Hepatitis C and HCC

·    Norah Terrault: Assessing HCC risk: who should undergo surveillance (this would include post SVR)

·    Greg Dore: Does the presence of HCC alter the response to HCV treatment

·    Antonio Craxi: Recurrence of HCC after Therapy for HCV: Fact or Fiction. 

·    Xavier Forns: Liver transplantation for HCC in hepatitis C: What are the issues

Download the symposium programme